Andrea Mohn-Staudner

1.3k total citations
23 papers, 245 citations indexed

About

Andrea Mohn-Staudner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Andrea Mohn-Staudner has authored 23 papers receiving a total of 245 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Andrea Mohn-Staudner's work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (10 papers). Andrea Mohn-Staudner is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (10 papers). Andrea Mohn-Staudner collaborates with scholars based in Austria, Chile and Egypt. Andrea Mohn-Staudner's co-authors include Robert Pirker, Stephan Madersbacher, H. Huber, Andrea Gsur, Klemens Trieb, Peter Hollaus, Christian Vutuc, M. Micksche, G. Krajnik and Gerald Haidinger and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Andrea Mohn-Staudner

23 papers receiving 240 citations

Peers

Andrea Mohn-Staudner
Kazunori Kamiya Japan
Włodzimierz Kupis Poland
Daniel Hughes United States
Xin-Biao Liao China
Lisheng Zhang China
Anne Katrine Johansen United States
Jo‐Ting Tsai Taiwan
Gaetana Porcelli Italy
Candace Wise United States
Alexandra M. Moore United States
Kazunori Kamiya Japan
Andrea Mohn-Staudner
Citations per year, relative to Andrea Mohn-Staudner Andrea Mohn-Staudner (= 1×) peers Kazunori Kamiya

Countries citing papers authored by Andrea Mohn-Staudner

Since Specialization
Citations

This map shows the geographic impact of Andrea Mohn-Staudner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Mohn-Staudner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Mohn-Staudner more than expected).

Fields of papers citing papers by Andrea Mohn-Staudner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Mohn-Staudner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Mohn-Staudner. The network helps show where Andrea Mohn-Staudner may publish in the future.

Co-authorship network of co-authors of Andrea Mohn-Staudner

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Mohn-Staudner. A scholar is included among the top collaborators of Andrea Mohn-Staudner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Mohn-Staudner. Andrea Mohn-Staudner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burghuber, Otto C., Klaus Kirchbacher, Andrea Mohn-Staudner, et al.. (2020). Results of the Austrian National Lung Cancer Audit. Clinical Medicine Insights Oncology. 14. 2282646292–2282646292. 5 indexed citations
2.
Hochmair, Maximilian J., Martin Filipits, Andrea Mohn-Staudner, et al.. (2017). P3.02b-101 EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib. Journal of Thoracic Oncology. 12(1). S1254–S1254. 2 indexed citations
3.
Buder, Anna, Maximilian J. Hochmair, Andrea Mohn-Staudner, et al.. (2017). P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC. Journal of Thoracic Oncology. 12(1). S1205–S1206. 2 indexed citations
4.
Popper, Helmut, Ulrike Gruber-Moesenbacher, Georg Hutarew, et al.. (2016). Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. memo - Magazine of European Medical Oncology. 9(4). 191–200. 1 indexed citations
5.
Hochmair, Maximilian J., Martin Filipits, Andrea Mohn-Staudner, et al.. (2016). EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.. Journal of Clinical Oncology. 34(15_suppl). e20572–e20572. 2 indexed citations
6.
Hilbe, Wolfgang, Ufuk Abacıoğlu, Daniel M. Aebersold, et al.. (2013). CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. memo - Magazine of European Medical Oncology. 6(2). 75–82. 1 indexed citations
7.
Popper, Helmut, Fritz Wrba, Ulrike Gruber-Moesenbacher, et al.. (2011). Histologie-basierter Algorithmus der molekularen Diagnostik des epidermalen Wachstumsfaktor-Rezeptorgens (Epidermal Growth Factor Receptor, EGFR) beim nicht-kleinzelligen Lungenkarzinom (non-small cell lung cancer, NSCLC)*. Wiener klinische Wochenschrift. 123(9-10). 316–321. 6 indexed citations
8.
Popper, Helmut, Fritz Wrba, Ulrike Gruber-Moesenbacher, et al.. (2011). A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)–in non-small-cell lung cancer (NSCLC)*. memo - Magazine of European Medical Oncology. 4(4). 248–253. 3 indexed citations
9.
Hilbe, Wolfgang, K Aigner, Christian Dittrich, et al.. (2007). Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom. Wiener klinische Wochenschrift. 119(7-8). 259–266. 9 indexed citations
10.
Prosch, Helmut, et al.. (2007). Cervical Ultrasound (US) and US-guided Lymph Node Biopsy as a Routine Procedure for Staging of Lung Cancer. Ultraschall in der Medizin - European Journal of Ultrasound. 28(6). 598–603. 27 indexed citations
11.
Douillard, Jean‐Yves, Bruno Coudert, Cesare Gridelli, et al.. (2007). 6507 ORAL Phase III study of IV vinflunine (VFL) versus IV docetaxel (DTX) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. European Journal of Cancer Supplements. 5(4). 358–358. 3 indexed citations
12.
Gsur, Andrea, Thomas Zidek, Gerald Haidinger, et al.. (2003). Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. British Journal of Cancer. 89(4). 702–706. 57 indexed citations
13.
Gsur, Andrea, Gerald Haidinger, Peter Hollaus, et al.. (2001). Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk.. PubMed. 21(3C). 2237–42. 22 indexed citations
14.
Krajnik, G., Andrea Mohn-Staudner, J. Thaler, et al.. (2000). Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial. Annals of Oncology. 11(8). 993–998. 34 indexed citations
15.
Pirker, Robert, G. Krajnik, Andrea Mohn-Staudner, et al.. (2000). Vinorelbine/gemcitabine in advanced non-small-cell lung cancer. Lung Cancer. 29(1). 46–46. 3 indexed citations
16.
Prior, C., W. Oberaigner, Andrea Mohn-Staudner, et al.. (1999). Advanced non-small-cell lung cancer: adjunctive interferon γ in induction and maintenance therapy. Journal of Cancer Research and Clinical Oncology. 125(1). 42–42. 9 indexed citations
17.
Krajnik, G., Wolfgang Wein, Richard Greil, et al.. (1998). Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. European Journal of Cancer. 34(12). 1977–1980. 20 indexed citations
18.
Mohn-Staudner, Andrea, H Vetter, Gerhard Baumgartner, et al.. (1996). Evaluation of Cyfra 21-1 as a marker for lung cancer.. PubMed. 108(15). 467–72. 2 indexed citations
19.
Drlicek, M., et al.. (1992). Circulating antineuronal antibodies reach neurons in vivo: an autopsy study. Journal of Neurology. 239(7). 407–410. 7 indexed citations
20.
Drlicek, M., et al.. (1991). [Circulating anti-neural antibodies, an indication of a subtype of small cell lung cancer?].. PubMed. 12(6). 311–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazunori Kamiya Breakdown of academic impact, for papers by Włodzimierz Kupis Breakdown of academic impact, for papers by Daniel Hughes Breakdown of academic impact, for papers by Xin-Biao Liao Breakdown of academic impact, for papers by Lisheng Zhang Breakdown of academic impact, for papers by Anne Katrine Johansen Breakdown of academic impact, for papers by Jo‐Ting Tsai Breakdown of academic impact, for papers by Gaetana Porcelli Breakdown of academic impact, for papers by Candace Wise Breakdown of academic impact, for papers by Alexandra M. Moore
Rankless by CCL
2026